bluuebunny/crossref_metadata_2025 huggingface dataset:
Data Supplement from Detection of Minimal Residual Disease in B Lymphoblastic Leukemia by High-Throughput Sequencing of IGH
Authors: Wu David , Emerson Ryan O. , Sherwood Anna , Loh Mignon L. , Angiolillo Anne , Howie Bryan , Vogt Jennifer , Rieder Mark , Kirsch Ilan , Carlson Christopher , Williamson David , Wood Brent L. , Robins Harlan
Published: April 2023

Supplementary Figure 1. Frequency of B cells with unique IGH rearrangements identified in bone marrow aspirates from 9 normal individuals. We performed multiplex PCR and sequencing to capture the IGH rearrangement repertoire present in the bone marrow samples of 9 healthy adults, and analyzed the frequency of the most common clones in each sample. The average frequency of the top clone was 0.8% of B cells, or ~0.08% of total nucleated cells. Above, the probability density of a normal distribution calculated using the geometric mean and standard deviation of top clone frequency is charted for this dataset.
Supplementary Figures 1-6, Supplementary Table 1, Supplementary Materials and Methods from Prevention of Colitis and Colitis-Associated Colorectal Cancer by a Novel Polypharmacological Histone Deacetylase Inhibitor
Authors: Wei Tzu-Tang , Lin Yi-Ting , Tseng Ruo-Yu , Shun Chia-Tung , Lin Yu-Chin , Wu Ming-Shiang , Fang Jim-Min , Chen Ching-Chow
Published: April 2023

Figure S1. JMF3171 and JMF3173 prevent acute colitis in vivo; Figure S2. Treatment of JMF3086 reduces endotoxin release in DSS-induced colitis mouse models; Figure S3. JMF3086 prevents tumor growth and induces protein acetylation in AOM/DSS mouse models; Figure S4. Accumulation of JMF3086 in colon tissues detects by LC-MS/MS and ESI-MS analyses; Figure S5. JMF3086 reduces the intracolonic infiltration of inflammatory cells and decreases COX-II expression at the sites of tumors in AOM/DSS mouse models; Figure S6. Treatment of JMF3086 does not exhibit any toxicity and apoptosis in vivo. Table S1. Primers for Real Time-Quantitative PCR.
Data Supplement from Detection of Minimal Residual Disease in B Lymphoblastic Leukemia by High-Throughput Sequencing of IGH
Authors: Wu David , Emerson Ryan O. , Sherwood Anna , Loh Mignon L. , Angiolillo Anne , Howie Bryan , Vogt Jennifer , Rieder Mark , Kirsch Ilan , Carlson Christopher , Williamson David , Wood Brent L. , Robins Harlan
Published: April 2023

Supplementary Figure 3. Estimation of PCR starting material using synthetic molecules. To validate our method for estimating the number of rearranged IGH loci present in our PCR starting material, we mixed fibroblast genomic DNA with B cell genomic DNA in a range of ratios, ranging from 0.07 to 300 ng of B cell gDNA in 300 ng total gDNA. We subsequently performed a multiplex PCR and sequencing reaction on these mixtures, comparing our estimation of the number of IGH rearrangements with the known number of B-cell genomes used in the starting material. Spiking in synthetic templates gives an excellent estimate of the number of rearranged IGH loci present in a PCR reaction.
Data Supplement from PI3K/mTOR Inhibition Markedly Potentiates HDAC Inhibitor Activity in NHL Cells through BIM- and MCL-1–Dependent Mechanisms In Vitro and In Vivo
Authors: Rahmani Mohamed , Aust Mandy Mayo , Benson Elisa C. , Wallace LaShanale , Friedberg Jonathan , Grant Steven
Published: April 2023

Legends to Supplementary Figures 1-8
Data Supplement from Detection of Minimal Residual Disease in B Lymphoblastic Leukemia by High-Throughput Sequencing of IGH
Authors: Wu David , Emerson Ryan O. , Sherwood Anna , Loh Mignon L. , Angiolillo Anne , Howie Bryan , Vogt Jennifer , Rieder Mark , Kirsch Ilan , Carlson Christopher , Williamson David , Wood Brent L. , Robins Harlan
Published: April 2023

Supplementary Table 1. Summary of immunophenotype of 5 cases with no clonal IGH gene rearrangement but abnormal B lymphoblast population by flow cytometry. Pre-treatment immunophenotype of neoplastic B lymphoblasts in samples in which no clonal IGH rearrangements (either complete VDJ and/or incomplete DJ) were detected above our criteria of 10%. CD antigen expression is descriptively scored as follows: L = low; I = intermediate; H = high; and - = negative.
Supplementary Table S1 from miR-409-3p/-5p Promotes Tumorigenesis, Epithelial-to-Mesenchymal Transition, and Bone Metastasis of Human Prostate Cancer
Authors: Josson Sajni , Gururajan Murali , Hu Peizhen , Shao Chen , Chu Gina Chia-Yi , Zhau Haiyen E. , Liu Chunyan , Lao Kaiqin , Lu Chia-Lun , Lu Yi-Tsung , Lichterman Jake , Nandana Srinivas , Li Quanlin , Rogatko Andre , Berel Dror , Posadas Edwin M. , Fazli Ladan , Sareen Dhruv , Chung Leland W.K.
Published: April 2023

Gleason scores of the cancer from which the TMA cores were obtained and the miR-409 intensity counts by ISH-QD. None of the TMA cores had any treatment.
Supplementary Methods, Figure Legends from miR-409-3p/-5p Promotes Tumorigenesis, Epithelial-to-Mesenchymal Transition, and Bone Metastasis of Human Prostate Cancer
Authors: Josson Sajni , Gururajan Murali , Hu Peizhen , Shao Chen , Chu Gina Chia-Yi , Zhau Haiyen E. , Liu Chunyan , Lao Kaiqin , Lu Chia-Lun , Lu Yi-Tsung , Lichterman Jake , Nandana Srinivas , Li Quanlin , Rogatko Andre , Berel Dror , Posadas Edwin M. , Fazli Ladan , Sareen Dhruv , Chung Leland W.K.
Published: April 2023

Supplementary Methods, Figure Legends from miR-409-3p/-5p Promotes Tumorigenesis, Epithelial-to-Mesenchymal Transition, and Bone Metastasis of Human Prostate Cancer
Supplementary Figure S3 from miR-409-3p/-5p Promotes Tumorigenesis, Epithelial-to-Mesenchymal Transition, and Bone Metastasis of Human Prostate Cancer
Authors: Josson Sajni , Gururajan Murali , Hu Peizhen , Shao Chen , Chu Gina Chia-Yi , Zhau Haiyen E. , Liu Chunyan , Lao Kaiqin , Lu Chia-Lun , Lu Yi-Tsung , Lichterman Jake , Nandana Srinivas , Li Quanlin , Rogatko Andre , Berel Dror , Posadas Edwin M. , Fazli Ladan , Sareen Dhruv , Chung Leland W.K.
Published: April 2023

A, Nanog and Oct-3/4 expression in tumor and stromal areas of prostates expressing miR-409 compared to control normal prostates, using IHC analysis. B, IHC staining of cytokeratin 8 (CK-8) and cytokeratin 5 (CK-5) in normal control prostate, and tumors of control and miR-409 expressing prostates.
Supplementary Figures 2 - 4 from Vascular Endothelial Growth Factor Pathway Polymorphisms as Prognostic and Pharmacogenetic Factors in Cancer: A Systematic Review and Meta-analysis
Authors: Eng Lawson , Azad Abul Kalam , Habbous Steven , Pang Vincent , Xu Wei , Maitland-van der Zee Anke H. , Savas Sevtap , Mackay Helen J. , Amir Eitan , Liu Geoffrey
Published: April 2023

PDF file, 141K, Supplementary Figures 2-4: These figures display the pooled meta-analysis results and forest plots of the other three VEGF polymorphisms analyzed (VEGF -2578C>A, -1154G>A, -460C>T).
Supplementary Figure 1 from Vascular Endothelial Growth Factor Pathway Polymorphisms as Prognostic and Pharmacogenetic Factors in Cancer: A Systematic Review and Meta-analysis
Authors: Eng Lawson , Azad Abul Kalam , Habbous Steven , Pang Vincent , Xu Wei , Maitland-van der Zee Anke H. , Savas Sevtap , Mackay Helen J. , Amir Eitan , Liu Geoffrey
Published: April 2023

PDF file, 160K, Supplementary Figure 1: This figure displays the forest plots for both the A) pooled and B) zygosity-segregated analysis of VEGF +936C>T as a prognostic marker of overall survival in cancer.
supplemental materials from ALDH1A3, the Major Aldehyde Dehydrogenase Isoform in Human Cholangiocarcinoma Cells, Affects Prognosis and Gemcitabine Resistance in Cholangiocarcinoma Patients
Authors: Chen Ming-Huang , Weng Jing-Jie , Cheng Chi-Tung , Wu Ren-Chin , Huang Shih-Chiang , Wu Chiao-En , Chung Yi-Hsiu , Liu Chun-Yu , Chang Mu-Hsin , Chen Ming-Han , Chiang Kun-Chun , Yeh Ta-Sen , Su Yeu , Yeh Chun-Nan
Published: April 2023

Supplemental table 1 summarized clinicopathological features of cholangiocarcinoma patients with high or low expression ALDH1A3 and Supplemental table 2 summarized Clinicopathological features of cholangiocarcinoma patients who received chemotherapy with high or low expression of ALDH1A3
Supplementary Table 3 from Differential Expression of 2′,3′-Cyclic-Nucleotide 3′-Phosphodiesterase and Neural Lineage Markers Correlate with Glioblastoma Xenograft Infiltration and Patient Survival
Authors: Zorniak Michael , Clark Paul A. , Leeper Heather E. , Tipping Matthew D. , Francis David M. , Kozak Kevin R. , Salamat M. Shahriar , Kuo John S.
Published: April 2023

PDF file, 60KB, Clinical characteristics of GBM tissue microarray.
Supplementary Table 1 from Differential Expression of 2′,3′-Cyclic-Nucleotide 3′-Phosphodiesterase and Neural Lineage Markers Correlate with Glioblastoma Xenograft Infiltration and Patient Survival
Authors: Zorniak Michael , Clark Paul A. , Leeper Heather E. , Tipping Matthew D. , Francis David M. , Kozak Kevin R. , Salamat M. Shahriar , Kuo John S.
Published: April 2023

PDF file, 84KB, Antibodies used for western analysis and subclassification of human glioblastoma stem-like cells.
Table S4 from Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer
Authors: Whatcott Clifford J. , Diep Caroline H. , Jiang Ping , Watanabe Aprill , LoBello Janine , Sima Chao , Hostetter Galen , Shepard H. Michael , Von Hoff Daniel D. , Han Haiyong
Published: April 2023

Table S4. Multivariate Analysis of clinicopathologic factors and IHC staining.
Supplementary Figure 6 from CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma
Authors: Rivera Zeyana , Ferrone Soldano , Wang Xinhui , Jube Sandro , Yang Haining , Pass Harvey I. , Kanodia Shreya , Gaudino Giovanni , Carbone Michele
Published: April 2023

PDF file, 2458K, CSPG4 knockdown decreases the rate of wound healing in MM cells.
Table S1 from Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer
Authors: Whatcott Clifford J. , Diep Caroline H. , Jiang Ping , Watanabe Aprill , LoBello Janine , Sima Chao , Hostetter Galen , Shepard H. Michael , Von Hoff Daniel D. , Han Haiyong
Published: April 2023

Table S1. Demographic data of 50 pancreatic cancer patients analyzed in our survival analysis.
Supplementary Figures S5-6. from Micrometastasis Volume in Lymph Nodes Determines Disease Recurrence Rate of Stage II Colorectal Cancer: A Prospective Multicenter Trial
Authors: Yamamoto Hirofumi , Murata Kohei , Fukunaga Mutsumi , Ohnishi Tadashi , Noura Shingo , Miyake Yasuhiro , Kato Takeshi , Ohtsuka Masahisa , Nakamura Yurika , Takemasa Ichiro , Mizushima Tsunekazu , Ikeda Masataka , Ohue Masayuki , Sekimoto Mitsugu , Nezu Riichiro , Matsuura Nariaki , Monden Morito , Doki Yuichiro , Mori Masaki
Published: April 2023

Figure S5: Impact of chemotherapy in High-MMV group. Post-operative chemotherapy was performed in 29 of 95 High-MMV cases and 2 of 201 Low-MMV cases. Irrespective of chemotherapy applied to High-MMV cases, High-MMV group consistently showed significantly worse 5-year DFS as compared to the Low-MMV group with no treatment (P= 0.009, 0.007). Similar results were observed in analyses for OS (P=0.003, 0.026).; Figure S6:Disease recurrence mode in stage II CRC. Among 296 patients, 51 developed disease recurrence after surgery. The recurrent organ site was 60 in all and are listed here. Like more advanced-stage patients, stage II patients had often hematogenous metastasis to liver and lung.
Supplementary Figure 1 from CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma
Authors: Rivera Zeyana , Ferrone Soldano , Wang Xinhui , Jube Sandro , Yang Haining , Pass Harvey I. , Kanodia Shreya , Gaudino Giovanni , Carbone Michele
Published: April 2023

PDF file, 1296K, Characterization of CSPG4 in Malignant Mesothelioma.
Supplementary Figure S7. Micrometastasis stayed mostly at pericolic nodes in node- negative CRCs. from Micrometastasis Volume in Lymph Nodes Determines Disease Recurrence Rate of Stage II Colorectal Cancer: A Prospective Multicenter Trial
Authors: Yamamoto Hirofumi , Murata Kohei , Fukunaga Mutsumi , Ohnishi Tadashi , Noura Shingo , Miyake Yasuhiro , Kato Takeshi , Ohtsuka Masahisa , Nakamura Yurika , Takemasa Ichiro , Mizushima Tsunekazu , Ikeda Masataka , Ohue Masayuki , Sekimoto Mitsugu , Nezu Riichiro , Matsuura Nariaki , Monden Morito , Doki Yuichiro , Mori Masaki
Published: April 2023

Of 55 node-negative CRCs (9 stage I and 46 stage II), Micrometastais was positive in 59 of 373 LNs (15.8%) at level 1, 16 of 193 LNs (8.3%) at level 2 and 4 of 86 LNs (4.7%) at level 3 through 5 slides inspection by immunostaining using pan-cytokeratin AE1/AE3 antibody (Dako). As results, 27 CRC cases were positive for micrometastasis in LNs. Micromstastasis was found at pericolic nodes adjacent to the tumor (level 1) in 26 cases of 27 CRCs (96.3%). On the other hand, micrometastasis stayed at intermediate nodes along the course of the main blood vessel, e.g., inferior mesenteric artery (level 2) and at central nodes around the root of the main blood vessel (level 3) in 37.0% and 14.8%, respectively. Level 1, pericolic nodes adjacent to the tumor; Level 2, intermediate nodes along the course of the main blood vessel; Level 3, central nodes around the root of the main blood vessel. Level 1, pericolic nodes adjacent to the tumor; Level 2, intermediate nodes along the course of the main blood vessel; Level 3, central nodes around the root of the main blood vessel.
Supplementary Figure S4. Randomization of chemotherapy in CEA band-positive CRC cases. from Micrometastasis Volume in Lymph Nodes Determines Disease Recurrence Rate of Stage II Colorectal Cancer: A Prospective Multicenter Trial
Authors: Yamamoto Hirofumi , Murata Kohei , Fukunaga Mutsumi , Ohnishi Tadashi , Noura Shingo , Miyake Yasuhiro , Kato Takeshi , Ohtsuka Masahisa , Nakamura Yurika , Takemasa Ichiro , Mizushima Tsunekazu , Ikeda Masataka , Ohue Masayuki , Sekimoto Mitsugu , Nezu Riichiro , Matsuura Nariaki , Monden Morito , Doki Yuichiro , Mori Masaki
Published: April 2023

Of CEA band-positive cases, 27 cases were randomly allocated and received post-operative chemotherapy using HCFU for one year, whereas 27 cases were randomly allocated to no treatment . There was no significant difference in 5-year DFS and 5-year OS between the two groups.
Supplementary Table 4 from Targeting Cancer Cells via the Reactive Oxygen Species-Mediated Unfolded Protein Response with a Novel Synthetic Polyphenol Conjugate
Authors: Shin Soon Young , Lee Jong Min , Lee Mi So , Koh Dongsoo , Jung Hyeryoung , Lim Yoongho , Lee Young Han
Published: April 2023

PDF file - 39K, Alterations in UPR-related gene expression in MIA PaCa-2 cells by 10 microM DPP-23.
Supplementary Figure S3. Survival analyses stratified by qRT-PCR (group a vs group b, vs group c+d). from Micrometastasis Volume in Lymph Nodes Determines Disease Recurrence Rate of Stage II Colorectal Cancer: A Prospective Multicenter Trial
Authors: Yamamoto Hirofumi , Murata Kohei , Fukunaga Mutsumi , Ohnishi Tadashi , Noura Shingo , Miyake Yasuhiro , Kato Takeshi , Ohtsuka Masahisa , Nakamura Yurika , Takemasa Ichiro , Mizushima Tsunekazu , Ikeda Masataka , Ohue Masayuki , Sekimoto Mitsugu , Nezu Riichiro , Matsuura Nariaki , Monden Morito , Doki Yuichiro , Mori Masaki
Published: April 2023

MM-free CRC group (group a, n=90) had a considerably favorable prognosis. (A) 5-year DFS: 5-year DSF was 93.3, 86.5, and 74.7% in group a, group b and group c+d (High-MMV), respectively. (B) 5-year OS: 5-year OS was 97.8, 95.5, and 89.5 % in group a, group b, and group c+d (High-MMV), respectively. (C) Final OS: final OS was 97.8, 93.7, and 86.3% in group a, group b, and group c+d (High-MMV), respectively.
Supplementary Table 1 from Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping
Authors: Wulfkuhle Julia D. , Berg Daniela , Wolff Claudia , Langer Rupert , Tran Kai , Illi Julie , Espina Virginia , Pierobon Mariaelena , Deng Jianghong , DeMichele Angela , Walch Axel , Bronger Holger , Becker Ingrid , Waldhör Christine , Höfler Heinz , Esserman Laura , Liotta Lance A. , Becker Karl-Friedrich , Petricoin Emanuel F.
Published: April 2023

PDF file - 54K, Antibodies used for Array and Western Blot Immunostaining
Supplementary Table 3 from Blocking and Randomization to Improve Molecular Biomarker Discovery
Authors: Qin Li-Xuan , Zhou Qin , Bogomolniy Faina , Villafania Liliana , Olvera Narciso , Cavatore Magali , Satagopan Jaya M. , Begg Colin B. , Levine Douglas A.
Published: April 2023

PDF file - 36KB, List of samples and their order in the non-randomized data.
Supplementary Table 2 from Blocking and Randomization to Improve Molecular Biomarker Discovery
Authors: Qin Li-Xuan , Zhou Qin , Bogomolniy Faina , Villafania Liliana , Olvera Narciso , Cavatore Magali , Satagopan Jaya M. , Begg Colin B. , Levine Douglas A.
Published: April 2023

PDF file - 40KB, List of differentially expressed markers (p-value <0.01) in the randomized data.
Supplementary Video 1. Recruitment of the Akt PH domain-EGFP with Trop-2 at the cell membrane from Trop-2 Induces Tumor Growth Through AKT and Determines Sensitivity to AKT Inhibitors
Authors: Guerra Emanuela , Trerotola Marco , Tripaldi Romina , Aloisi Anna Laura , Simeone Pasquale , Sacchetti Andrea , Relli Valeria , D'Amore Antonella , La Sorda Rossana , Lattanzio Rossano , Piantelli Mauro , Alberti Saverio
Published: April 2023

This video shows MTE 4-14 cells cotransfected with Akt PH domain-EGFP (green) and Trop-2-mRFP1 (red). Recruitment and colocalization of Akt PH domain-EGFP with Trop-2-mRFP1 at the cell membrane was found to be quantitative and dynamic. The time lapse covers a period of about 27 min.
Supplementary Information from Trop-2 Induces Tumor Growth Through AKT and Determines Sensitivity to AKT Inhibitors
Authors: Guerra Emanuela , Trerotola Marco , Tripaldi Romina , Aloisi Anna Laura , Simeone Pasquale , Sacchetti Andrea , Relli Valeria , D'Amore Antonella , La Sorda Rossana , Lattanzio Rossano , Piantelli Mauro , Alberti Saverio
Published: April 2023

Supplementary Methods: Protein microarrays,Multiplex Western blotting,Confocal time-lapse microscopy, Western blotting, Immunohistochemistry, 3D structure analysis; Supplementary Table 3:Breast cancer case series clinical and pathological parameters; the file also contains legends for Supplementary Figures 1-6.
Supplementary Figure 1 from Blocking and Randomization to Improve Molecular Biomarker Discovery
Authors: Qin Li-Xuan , Zhou Qin , Bogomolniy Faina , Villafania Liliana , Olvera Narciso , Cavatore Magali , Satagopan Jaya M. , Begg Colin B. , Levine Douglas A.
Published: April 2023

PDF file - 175KB, Standard deviation between replicates for each marker in the randomized data.
Data Supplement from A Novel KLF4/LDHA Signaling Pathway Regulates Aerobic Glycolysis in and Progression of Pancreatic Cancer
Authors: Shi Min , Cui Jiujie , Du Jiawei , Wei Daoyan , Jia Zhiliang , Zhang Jun , Zhu Zhenggang , Gao Yong , Xie Keping
Published: April 2023

Supplementary Figure S1. KLF4, LDHA, and LDHB expression in pancreatic tumor and normal pancreatic tissue specimens. Supplementary Figure S2. LDHB expression in pancreatic tumor specimens. Supplementary Figure S3. KLF4 expression in pancreatic tumor specimens and its association with clinicopathologic features of pancreatic cancer patients Supplementary Figure S4. The effect of KLF4/LDHA signaling on cell growth of pancreatic cancer in vitro. Supplementary Figure S5. The effect of KLF4 expression on the growth of pancreatic cancer cells.
Supplementary Table 1 from miR-141 Is a Key Regulator of Renal Cell Carcinoma Proliferation and Metastasis by Controlling EphA2 Expression
Authors: Chen Xuanyu , Wang Xuegang , Ruan Anming , Han Weiwei , Zhao Yan , Lu Xing , Xiao Pei , Shi Hangchuan , Wang Rong , Chen Li , Chen Shaoyong , Du Quansheng , Yang Hongmei , Zhang Xiaoping
Published: April 2023

PDF file - 62K, Statistic characterization of ccRCC patients and tumors for molecular signature analyses (2008-2013).
Supplementary Figure 1, Figure 2, Figure 3 from Elevated Serum Angiopoietin-like Protein 2 Correlates with the Metastatic Properties of Colorectal Cancer: A Serum Biomarker for Early Diagnosis and Recurrence
Authors: Toiyama Yuji , Tanaka Koji , Kitajima Takahito , Shimura Tadanobu , Kawamura Mikio , Kawamoto Aya , Okugawa Yoshinaga , Saigusa Susumu , Hiro Junichiro , Inoue Yasuhiro , Mohri Yasuhiko , Goel Ajay , Kusunoki Masato
Published: April 2023

Supplementary Figure 1, Figure 2, Figure 3. Representative photomicrographs detailing immunohistochemical analysis of ANGPTL2 expression, Figure S2: ANGPTL2 expression in 5 colorectal cancer cell lines, Figure S3: Receiver operating characteristics curve analysis using serum ANGPTL2 for distinguishing patients with CRC with normal CEA levels from normal controls (NC).
Supplementary Figure 3 from miR-141 Is a Key Regulator of Renal Cell Carcinoma Proliferation and Metastasis by Controlling EphA2 Expression
Authors: Chen Xuanyu , Wang Xuegang , Ruan Anming , Han Weiwei , Zhao Yan , Lu Xing , Xiao Pei , Shi Hangchuan , Wang Rong , Chen Li , Chen Shaoyong , Du Quansheng , Yang Hongmei , Zhang Xiaoping
Published: April 2023

PDF file - 595K, miR-141 acts as a tumor-suppressor in RCC.
Supplementary Figure 2 from miR-141 Is a Key Regulator of Renal Cell Carcinoma Proliferation and Metastasis by Controlling EphA2 Expression
Authors: Chen Xuanyu , Wang Xuegang , Ruan Anming , Han Weiwei , Zhao Yan , Lu Xing , Xiao Pei , Shi Hangchuan , Wang Rong , Chen Li , Chen Shaoyong , Du Quansheng , Yang Hongmei , Zhang Xiaoping
Published: April 2023

PDF file - 160K, Validation of miR-141 overexpression in two RCC cell lines 786-O and SN12-PM6 infected with lentiviruses.
Supplemental Figures 1-6 from Podoplanin-Positive Cancer-Associated Fibroblasts in the Tumor Microenvironment Induce Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma with EGFR Mutation
Authors: Yoshida Tatsuya , Ishii Genichiro , Goto Koichi , Neri Shinya , Hashimoto Hiroko , Yoh Kiyotaka , Niho Seiji , Umemura Shigeki , Matsumoto Shingo , Ohmatsu Hironobu , Iida Shinsuke , Niimi Akio , Nagai Kanji , Ohe Yuichiro , Ochiai Atsushi
Published: April 2023

Supplemental Figures 1-6. Supplemental Figure 1: Fluorescence microscopy showing mRFP-labeled PC-9 (red) and Venus-labeled CAFs (green) with or without gefitinib treatment. Supplemental Figure 2: mRNA levels of podoplanin (PDPN) in CAF-Ctrl and CAF PDPN-WT. Supplemental Figure 3: Co-culture with other CAFs induces gefitinib resistance. mRFP-labeled PC-9 and HCC-827 cells were co-cultured with CAFs (CAF-Ctrl, PDPN-WT, or CAF-PDPN-Del.IC) in the presence or absence of gefitinib treatment. The total cell numbers of PC-9 or HCC-827 cells treated for 72 hours with gefitinib in the presence or absence of Venus-labeled CAF-Ctrl, PDPN-WT, or CAF-PDPN-Del.IC are shown. Supplemental Figure 4: The number of the cases according to the PDPN-positive CAF area/stromal area (%). Supplemental Figure 5: PFS according to podoplanin expression in patients with EGFR common mutations (exon 19 deletion and L858R). Supplemental Figure 6: mRNA levels of HGF in CAF-Ctrl and CAF PDPN-WT.
Supplementary Table 2 from Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab
Authors: Bossi Paolo , Bergamini Cristiana , Siano Marco , Cossu Rocca Maria , Sponghini Andrea P. , Favales Federica , Giannoccaro Marco , Marchesi Edoardo , Cortelazzi Barbara , Perrone Federica , Pilotti Silvana , Locati Laura D. , Licitra Lisa , Canevari Silvana , De Cecco Loris
Published: April 2023

Supplementary Table S2 Gene sets associated to long- and short-PFS patients
Supplementary Figure 4 from Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab
Authors: Bossi Paolo , Bergamini Cristiana , Siano Marco , Cossu Rocca Maria , Sponghini Andrea P. , Favales Federica , Giannoccaro Marco , Marchesi Edoardo , Cortelazzi Barbara , Perrone Federica , Pilotti Silvana , Locati Laura D. , Licitra Lisa , Canevari Silvana , De Cecco Loris
Published: April 2023

Fig S4. Ability of existing gene signatures to predict outcome following cetuximab treatment. Five available prognostic gene-expression based signatures were taken into account: i) the hypoxia metagene (Winter, 2007); ii) the 13-gene OSCC signature (Lohavanichbutr, 2013); iii) the RSI-index (Eschrich, 2009); iv) the 42-gene Chung's high risk signature (Chung, 2006); v) the 172-gene signature (De Cecco, 2014). A score was assessed for each sample entering into our study following the model developed by the authors and compared among long- and short PFS cases. The boxplots depicts the data in the two groups. Green: long-PFS; Red: short-PFS.
Supplementary Figure S1 and Tables S1-3 from Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes
Authors: Tsai Shu-Chun , Shih Lee-Yung , Liang Sung-Tzu , Huang Ying-Jung , Kuo Ming-Chung , Huang Chein-Fuang , Shih Yu-Shu , Lin Tung-Huei , Chiu Ming-Chun , Liang Der-Cherng
Published: April 2023

Supplementary Figure S1 and Tables S1-3. Figure S1. Frequencies and distribution of co-operating mutations in RUNX1 mutationpositive patients. Table S1. Comparison of clinicohematological characteristics according to the biological activities of RUNX1 in MDS and CMML. Table S2. Correlation of risk of sAML transformation with RUNX1activities or co-existing gene mutations in MDS and CMML patients carrying RUNX1 mutations. Table S3. Correlation of sAML-free survival with cytogenetics or additional co-existing gene mutations in MDS and CMML patients carrying RUNX1 mutations. Supplemental methods and References
Supplementary Textbox from Rare Cancer Trial Design: Lessons from FDA Approvals
Authors: Gaddipati Himabindu , Liu Ke , Pariser Anne , Pazdur Richard
Published: April 2023

PDF file, 129KB, Definitions of Selected Regulatory Terms.
supplementary Figure 3 from Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma
Authors: Hu Bo , Yang Xin-Rong , Xu Yang , Sun Yun-Fan , Sun Chao , Guo Wei , Zhang Xin , Wang Wei-Min , Qiu Shuang-Jian , Zhou Jian , Fan Jia
Published: April 2023

Supplementary figure S3. (A) Kaplan-Meier analysis of OS and RFS for NLR in the validation cohort; (B) Kaplan-Meier analysis of OS and RFS for PLR in the validation cohort.
Supplementary Tables 1 - 2 from Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma
Authors: Hu Bo , Yang Xin-Rong , Xu Yang , Sun Yun-Fan , Sun Chao , Guo Wei , Zhang Xin , Wang Wei-Min , Qiu Shuang-Jian , Zhou Jian , Fan Jia
Published: April 2023

Supplementary Table S1. Correlation between the SII and clinicopathological characteristics (training cohort, n=133 and validation cohort, n=123). Supplementary Table S2. Correlation Between SII, NLR and PLR and clinicopathological characteristics in training and validation cohorts.
Supplementary Methods, Tables 1 - 9 from Concurrent Alterations in TERT, KDM6A, and the BRCA Pathway in Bladder Cancer
Authors: Nickerson Michael L. , Dancik Garrett M. , Im Kate M. , Edwards Michael G. , Turan Sevilay , Brown Joseph , Ruiz-Rodriguez Christina , Owens Charles , Costello James C. , Guo Guangwu , Tsang Shirley X. , Li Yingrui , Zhou Quan , Cai Zhiming , Moore Lee E. , Lucia M. Scott , Dean Michael , Theodorescu Dan
Published: April 2023

Supplementary Table S1 presents the clinical characteristics of patients and tumors analyzed in the study. Supplementary Table S2 contains the details about next generation sequencing of the tumor exomes, mapped reads, target depth, and target coverage. Supplementary Table S3 shows the somatic variants that were confirmed by PCR and Sanger sequencing of tumor-normal DNA. Supplementary Table S4 shows the germline variants that were confirmed by PCR and Sanger sequencing of tumor-normal DNA. Supplementary Table S5 includes details about bladder tumor samples with somatic BAP1 mutations. Supplementary Table S6 includes details about the somatic and germline variants that were characterized in the proximal TERT promoter. Supplementary Table S7 examines associations between altered genes to determine if the mutations in different cancer genes were correlated. Supplementary Table S8 shows the genes and biological functions that are associated with interaction networks that include the frequently altered bladder cancer genes. Supplementary Table S9 presents details about the microarray gene expression datasets that were used for the network and gene expression analyses.
Supplementary Figure S1 from Concurrent Alterations in TERT, KDM6A, and the BRCA Pathway in Bladder Cancer
Authors: Nickerson Michael L. , Dancik Garrett M. , Im Kate M. , Edwards Michael G. , Turan Sevilay , Brown Joseph , Ruiz-Rodriguez Christina , Owens Charles , Costello James C. , Guo Guangwu , Tsang Shirley X. , Li Yingrui , Zhou Quan , Cai Zhiming , Moore Lee E. , Lucia M. Scott , Dean Michael , Theodorescu Dan
Published: April 2023

The ubiquitin C (UBC) network in bladder cancer.
Data Supplement from Excess of Proximal Microsatellite-Stable Colorectal Cancer in African Americans from a Multiethnic Study
Authors: Xicola Rosa M. , Gagnon Molly , Clark Julia R. , Carroll Timothy , Gao Weihua , Fernandez Christian , Mijic Dragana , Rawson James B. , Janoski Ashley , Pusatcioglu Cenk K. , Rajaram Priyanka , Gluskin Adam B. , Regan Maureen , Chaudhry Vivek , Abcarian Herand , Blumetti Jennifer , Cintron Jose , Melson Joshua , Xie Hui , Guzman Grace , Emmadi Rajyasree , Alagiozian-Angelova Victoria , Kupfer Sonia S. , Braunschweig Carol , Ellis Nathan A. , Llor Xavier
Published: April 2023

Supplementary Table 2: The combined data shows comparable incidence of MSI between AAs and NHWs
Data Supplement from Excess of Proximal Microsatellite-Stable Colorectal Cancer in African Americans from a Multiethnic Study
Authors: Xicola Rosa M. , Gagnon Molly , Clark Julia R. , Carroll Timothy , Gao Weihua , Fernandez Christian , Mijic Dragana , Rawson James B. , Janoski Ashley , Pusatcioglu Cenk K. , Rajaram Priyanka , Gluskin Adam B. , Regan Maureen , Chaudhry Vivek , Abcarian Herand , Blumetti Jennifer , Cintron Jose , Melson Joshua , Xie Hui , Guzman Grace , Emmadi Rajyasree , Alagiozian-Angelova Victoria , Kupfer Sonia S. , Braunschweig Carol , Ellis Nathan A. , Llor Xavier
Published: April 2023

Supplementary Figure 1 (A) Age of diagnosis trends: there has been a progressive decrease in diagnosis at the older age groups and an increase at younger ages. (B) Stage at diagnosis trends: there has been an increase in localized CRCs along with a decrease in regional cancers as well as a slight increase in metastatic cases. (C) Stage by age at diagnosis: younger individuals present with more advanced CRCs. Patients with no available information for staging were excluded from the analysis
Data Supplement from Excess of Proximal Microsatellite-Stable Colorectal Cancer in African Americans from a Multiethnic Study
Authors: Xicola Rosa M. , Gagnon Molly , Clark Julia R. , Carroll Timothy , Gao Weihua , Fernandez Christian , Mijic Dragana , Rawson James B. , Janoski Ashley , Pusatcioglu Cenk K. , Rajaram Priyanka , Gluskin Adam B. , Regan Maureen , Chaudhry Vivek , Abcarian Herand , Blumetti Jennifer , Cintron Jose , Melson Joshua , Xie Hui , Guzman Grace , Emmadi Rajyasree , Alagiozian-Angelova Victoria , Kupfer Sonia S. , Braunschweig Carol , Ellis Nathan A. , Llor Xavier
Published: April 2023

Supplementary Figure Legend
Supplementary Table 3 from Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303
Authors: Psyrri Amanda , Lee Ju-Whei , Pectasides Eirini , Vassilakopoulou Maria , Kosmidis Efstratios K. , Burtness Barbara A. , Rimm David L. , Wanebo Harold J. , Forastiere Arlene A.
Published: April 2023

PDF file - 67K, Odds Ratio and Hazard Ratio (with 95% Confidence Interval) with A Unit Increase in the Form of log10 Transformation in AQUA Scores by Biomarker.
Supplementary Table 2 from Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303
Authors: Psyrri Amanda , Lee Ju-Whei , Pectasides Eirini , Vassilakopoulou Maria , Kosmidis Efstratios K. , Burtness Barbara A. , Rimm David L. , Wanebo Harold J. , Forastiere Arlene A.
Published: April 2023

PDF file - 64K, Summary of Biomarker AQUA Scores at Baseline.
Supplementary Table 1 from Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303
Authors: Psyrri Amanda , Lee Ju-Whei , Pectasides Eirini , Vassilakopoulou Maria , Kosmidis Efstratios K. , Burtness Barbara A. , Rimm David L. , Wanebo Harold J. , Forastiere Arlene A.
Published: April 2023

PDF file - 81K, Primary antibodies Used for Immunohistochemistry.
Supplementary Figure 1 from Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303
Authors: Psyrri Amanda , Lee Ju-Whei , Pectasides Eirini , Vassilakopoulou Maria , Kosmidis Efstratios K. , Burtness Barbara A. , Rimm David L. , Wanebo Harold J. , Forastiere Arlene A.
Published: April 2023

PDF file - 65K, REMARK Flow Chart of E2303 translational research study.
Data Supplement from Discordant In Vitro and In Vivo Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts
Authors: Gupta Shiv K. , Mladek Ann C. , Carlson Brett L. , Boakye-Agyeman Felix , Bakken Katrina K. , Kizilbash Sani H. , Schroeder Mark A. , Reid Joel , Sarkaria Jann N.
Published: April 2023

Supplementary Figure S1. Sustained PARP inhibition by single Veliparib treatment and the effect of repeated drug treatment on cell growth in vitro
Supplementary Figure S5 from CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell–Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1
Authors: Lee Yunqin , Shin June Ho , Longmire Michelle , Wang Hua , Kohrt Holbrook E. , Chang Howard Y. , Sunwoo John B.
Published: April 2023

Supplementary Figure S5. Full-length Western blots corresponding to truncated blots shown in Fig 3.
Supplementary Figure S4 from CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell–Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1
Authors: Lee Yunqin , Shin June Ho , Longmire Michelle , Wang Hua , Kohrt Holbrook E. , Chang Howard Y. , Sunwoo John B.
Published: April 2023

Supplementary Figure S4. Anti-PD-1 blockade partially restores IFNÃŽÂ³ secretion by TILs against CD44+ SCCHN cells.
Supplementary Figure S3 from CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell–Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1
Authors: Lee Yunqin , Shin June Ho , Longmire Michelle , Wang Hua , Kohrt Holbrook E. , Chang Howard Y. , Sunwoo John B.
Published: April 2023

Supplementary Figure S3. CD44+CD271- and CD44+CD271+ cells express comparable levels of PD-L1 in human SCCHN tumors.
Data Supplement from Discordant In Vitro and In Vivo Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts
Authors: Gupta Shiv K. , Mladek Ann C. , Carlson Brett L. , Boakye-Agyeman Felix , Bakken Katrina K. , Kizilbash Sani H. , Schroeder Mark A. , Reid Joel , Sarkaria Jann N.
Published: April 2023

Supplementary Figure S6. Measurements of tumor growth after treatment with veliparib, TMZ or their combination in TMZ-sensitive versus resistant GBM models in vivo.
Data Supplement from Squamous Cell Carcinoma of the Oral Tongue in Young Non-Smokers Is Genomically Similar to Tumors in Older Smokers
Authors: Pickering Curtis R. , Zhang Jiexin , Neskey David M. , Zhao Mei , Jasser Samar A. , Wang Jiping , Ward Alexandra , Tsai C. Jillian , Ortega Alves Marcus V. , Zhou Jane H. , Drummond Jennifer , El-Naggar Adel K. , Gibbs Richard , Weinstein John N. , Wheeler David A. , Wang Jing , Frederick Mitchell J. , Myers Jeffrey N.
Published: April 2023

Supplementary Table 1. Clinical characteristics.
Data Supplement from Squamous Cell Carcinoma of the Oral Tongue in Young Non-Smokers Is Genomically Similar to Tumors in Older Smokers
Authors: Pickering Curtis R. , Zhang Jiexin , Neskey David M. , Zhao Mei , Jasser Samar A. , Wang Jiping , Ward Alexandra , Tsai C. Jillian , Ortega Alves Marcus V. , Zhou Jane H. , Drummond Jennifer , El-Naggar Adel K. , Gibbs Richard , Weinstein John N. , Wheeler David A. , Wang Jing , Frederick Mitchell J. , Myers Jeffrey N.
Published: April 2023

Supplementary Figure S2. Analysis of mutation profiles.
Supplementary Figure 2 from Lack of Immunomodulatory Interleukin-27 Enhances Oncogenic Properties of Mutant p53 In Vivo
Authors: Dibra Denada , Mitra Abhisek , Newman Melisa , Xia Xueqing , Cutrera Jeffry J. , Gagea Mihai , Kleinerman Eugenie S. , Lozano Guillermina , Li Shulin
Published: April 2023

Supplementary Figure 2: Osteosarcomas developing in IL27RA-/- p53R172H/+ mice are aggressive and transplantable. (
Supplementary Figure 2 from Prognostic Significance of AKT/mTOR and MAPK Pathways and Antitumor Effect of mTOR Inhibitor in NF1-Related and Sporadic Malignant Peripheral Nerve Sheath Tumors
Authors: Endo Makoto , Yamamoto Hidetaka , Setsu Nokitaka , Kohashi Kenichi , Takahashi Yusuke , Ishii Takeaki , Iida Kei-ichiro , Matsumoto Yoshihiro , Hakozaki Michiyuki , Aoki Mikiko , Iwasaki Hiroshi , Dobashi Yoh , Nishiyama Kenichi , Iwamoto Yukihide , Oda Yoshinao
Published: April 2023

PDF file - 268K, Western blotting (WB) for p-AKT, (total) AKT, p-mTOR, (total) mTOR, p-S6RP, p-p70S6K, p-MEK1/2, and p-ERK1/2 using frozen tumor samples and corresponding normal tissue. Positive or negative staining (P: positive; N: negative) on immunohistochemistry (IHC) is shown above each band to be compared with the WB results. The expression levels in WB correspond closely to those in IHC. p-AKT, p-mTOR, and p-p70S6K show stronger expression in tumor samples than in normal tissue in both NF1-related (Case 1, 2 and 3) and sporadic (Case 4 and 5) MPNSTs, while this tendency was not apparent for p-MEK1/2 and p-ERK1/2.
Table S1 from SIRT6 Overexpression Potentiates Apoptosis Evasion in Hepatocellular Carcinoma via BCL2-Associated X Protein–Dependent Apoptotic Pathway
Authors: Ran Long-Kuan , Chen Yong , Zhang Zhen-Zhen , Tao Na-Na , Ren Ji-Hua , Zhou Li , Tang Hua , Chen Xiang , Chen Ke , Li Wan-Yu , Huang Ai-Long , Chen Juan
Published: April 2023

Primers of real-time PCR
Supplementary Figure 6 from Prospero Homeobox 1 Promotes Epithelial–Mesenchymal Transition in Colon Cancer Cells by Inhibiting E-cadherin via miR-9
Authors: Lu Mei-Hsuan , Huang Chao-Cheng , Pan Mei-Ren , Chen Hong-Hwa , Hung Wen-Chun
Published: April 2023

PDF file - 79K, MiR-9 level is higher in tumor tissues with high PROX1 and low E-cadherin expression
Supplementary Figure 1 from Adaptive Dosing Approaches to the Individualization of 13-Cis-Retinoic Acid (Isotretinoin) Treatment for Children with High-Risk Neuroblastoma
Authors: Veal Gareth J. , Errington Julie , Rowbotham Sophie E. , Illingworth Nicola A. , Malik Ghada , Cole Michael , Daly Ann K. , Pearson Andrew D.J. , Boddy Alan V.
Published: April 2023

PDF file - 72K, Observed and fitted 13-cisRA data from four patients
Supplementary Figure 4 from Prospero Homeobox 1 Promotes Epithelial–Mesenchymal Transition in Colon Cancer Cells by Inhibiting E-cadherin via miR-9
Authors: Lu Mei-Hsuan , Huang Chao-Cheng , Pan Mei-Ren , Chen Hong-Hwa , Hung Wen-Chun
Published: April 2023

PDF file - 78K, PROX1 increased miR-9 expression in WiDr cells
Supplementary Table 1 from Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma
Authors: Kim Edward J. , Sahai Vaibhav , Abel Ethan V. , Griffith Kent A. , Greenson Joel K. , Takebe Naoko , Khan Gazala N. , Blau John L. , Craig Ronald , Balis Ulysses G. , Zalupski Mark M. , Simeone Diane M.
Published: April 2023

Supplementary Table 1. Summary of Treatment-Related Adverse Events
Supplementary Figure 1 from Prospero Homeobox 1 Promotes Epithelial–Mesenchymal Transition in Colon Cancer Cells by Inhibiting E-cadherin via miR-9
Authors: Lu Mei-Hsuan , Huang Chao-Cheng , Pan Mei-Ren , Chen Hong-Hwa , Hung Wen-Chun
Published: April 2023

PDF file - 135K, The sequence of RT-PCR primers used
Supplementary Figure 2 from Calreticulin Promotes Migration and Invasion of Esophageal Cancer Cells by Upregulating Neuropilin-1 Expression via STAT5A
Authors: Shi Feng , Shang Li , Pan Bei-Qing , Wang Xiao-Min , Jiang Yan-Yi , Hao Jia-Jie , Zhang Yu , Cai Yan , Xu Xin , Zhan Qi-Min , Wang Ming-Rong
Published: April 2023

Supplementary Figure 2. Quantitative real-time PCR analysis of STAT5A and STAT5B expression in ESCC cells transiently transfected with non-silencing siRNA, STAT5A siRNA or STAT5B siRNA. Columns, mean; Bars, SD (n = 3); **, P < 0.01.
Supplemental Methods, Supplementary Figures 1-4, Supplementary Table 1 from Integrated Whole Genome and Transcriptome Analysis Identified a Therapeutic Minor Histocompatibility Antigen in a Splice Variant of ITGB2
Authors: Pont Margot J. , van der Lee Dyantha I. , van der Meijden Edith D. , van Bergen Cornelis A.M. , Kester Michel G.D. , Honders Maria W. , Vermaat Martijn , Eefting Matthias , Marijt Erik W.A. , Kielbasa Szymon M. , Hoen Peter A.C. 't , Falkenburg J.H. Frederik , Griffioen Marieke
Published: April 2023

Supplemental Figure 1: RNA-sequence analysis allows discovery of antigens generated by exon skipping; Supplemental Figure 2: Sequence composition of the alternative HMSD transcript; Supplemental Figure 3: T-cells for LB-ITGB2-1 are detected after DLI; Supplemental Figure 4: Ex vivo activation of LB-ITGB2-1 specific T-cells; Table S1: predicted peptides for HMSD
Data Supplement from Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses
Authors: Tsimberidou Apostolia-Maria , Wen Sijin , Hong David S. , Wheler Jennifer J. , Falchook Gerald S. , Fu Siqing , Piha-Paul Sarina , Naing Aung , Janku Filip , Aldape Kenneth , Ye Yang , Kurzrock Razelle , Berry Donald
Published: April 2023

Supplemental Table 3. Types of agents used in patients treated with matched or non-matched therapy
Supplementary Table 3 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
Authors: Oberthuer André , Juraeva Dilafruz , Hero Barbara , Volland Ruth , Sterz Carolina , Schmidt Rene , Faldum Andreas , Kahlert Yvonne , Engesser Anne , Asgharzadeh Shahab , Seeger Robert , Ohira Miki , Nakagawara Akira , Scaruffi Paola , Tonini Gian Paolo , Janoueix-Lerosey Isabelle , Delattre Olivier , Schleiermacher Gudrun , Vandesompele Jo , Speleman Frank , Noguera Rosa , Piqueras Marta , Bénard Jean , Valent Alexander , Avigad Smadar , Yaniv Isaac , Grundy Richard G. , Ortmann Monika , Shao Chunxuan , Schwab Manfred , Eils Roland , Simon Thorsten , Theissen Jessica , Berthold Frank , Westermann Frank , Brors Benedikt , Fischer Matthias
Published: April 2023

Supplementary Table 3. This table summarizes the results of the Kaplan-Meier estimates for both EFS and OS of clinically relevant subgroups of neuroblastoma patients according to classification by the four remaining classifiers SVM_th22, SVM_th24, SVM_th26 and SVM_th44.
Workflow and the Experimental Strategies from Cervical Cancer Stem Cells Selectively Overexpress HPV Oncoprotein E6 that Controls Stemness and Self-Renewal through Upregulation of HES1
Authors: Tyagi Abhishek , Vishnoi Kanchan , Mahata Sutapa , Verma Gaurav , Srivastava Yogesh , Masaldan Shashank , Roy Bal Gangadhar , Bharti Alok C. , Das Bhudev C.
Published: April 2023

Workflow and the Experimental Strategies
Supplementary Table from Cervical Cancer Stem Cells Selectively Overexpress HPV Oncoprotein E6 that Controls Stemness and Self-Renewal through Upregulation of HES1
Authors: Tyagi Abhishek , Vishnoi Kanchan , Mahata Sutapa , Verma Gaurav , Srivastava Yogesh , Masaldan Shashank , Roy Bal Gangadhar , Bharti Alok C. , Das Bhudev C.
Published: April 2023

Table 1: List of real-time RT-PCR primers used in the study Table 2: Result of cervical cancer cell line or primary culture derived xenografting in nude mice Table 3: Physical state of HPV16 DNA in CINI/II, CINIII/IV cervical cancer lesions and primary xenograft
Fig. S4 from Cervical Cancer Stem Cells Selectively Overexpress HPV Oncoprotein E6 that Controls Stemness and Self-Renewal through Upregulation of HES1
Authors: Tyagi Abhishek , Vishnoi Kanchan , Mahata Sutapa , Verma Gaurav , Srivastava Yogesh , Masaldan Shashank , Roy Bal Gangadhar , Bharti Alok C. , Das Bhudev C.
Published: April 2023

Fig. S4 SP cells show accumulation of slow dividing cells and express pluripotency markers Oct4 and Nanog.
Supplementary Figure S2 from Promoter Methylation of CDO1 Identifies Clear-Cell Renal Cell Cancer Patients with Poor Survival Outcome
Authors: Deckers Ivette A.G. , Schouten Leo J. , Van Neste Leander , van Vlodrop Iris J.H. , Soetekouw Patricia M.M.B. , Baldewijns Marcella M.L.L. , Jeschke Jana , Ahuja Nita , Herman James G. , van den Brandt Piet A. , van Engeland Manon
Published: April 2023

Five-year survival of clear-cell renal cell cancer patients from the TCGA according to CDO1 methylation in patients A) aged <55 years, B) aged {greater than or equal to}55 to <65 years, C) aged {greater than or equal to} 65 to <75 years and D) aged {greater than or equal to}75 years at diagnosis.
Fig. S3 from Cervical Cancer Stem Cells Selectively Overexpress HPV Oncoprotein E6 that Controls Stemness and Self-Renewal through Upregulation of HES1
Authors: Tyagi Abhishek , Vishnoi Kanchan , Mahata Sutapa , Verma Gaurav , Srivastava Yogesh , Masaldan Shashank , Roy Bal Gangadhar , Bharti Alok C. , Das Bhudev C.
Published: April 2023

Fig. S3 Cell surface analysis of SP and Non-SP cells reveal phenotypically and functionally distinct populations.
Supplementary Figure Legends from Promoter Methylation of CDO1 Identifies Clear-Cell Renal Cell Cancer Patients with Poor Survival Outcome
Authors: Deckers Ivette A.G. , Schouten Leo J. , Van Neste Leander , van Vlodrop Iris J.H. , Soetekouw Patricia M.M.B. , Baldewijns Marcella M.L.L. , Jeschke Jana , Ahuja Nita , Herman James G. , van den Brandt Piet A. , van Engeland Manon
Published: April 2023

Supplementary Figure Legends
Fig. S2 from Cervical Cancer Stem Cells Selectively Overexpress HPV Oncoprotein E6 that Controls Stemness and Self-Renewal through Upregulation of HES1
Authors: Tyagi Abhishek , Vishnoi Kanchan , Mahata Sutapa , Verma Gaurav , Srivastava Yogesh , Masaldan Shashank , Roy Bal Gangadhar , Bharti Alok C. , Das Bhudev C.
Published: April 2023

Fig. S2 Flowcytometric analysis of CD49f and CD71 expression on SiHa (HPV16+ve), HeLa (HPV18+ve) and C33a (HPV-ve) parent cultures.
Supplemental Figure 2. from VEGF Potentiates GD3-Mediated Immunosuppression by Human Ovarian Cancer Cells
Authors: Tiper Irina V. , Temkin Sarah M. , Spiegel Sarah , Goldblum Simeon E. , Giuntoli Robert L. , Oelke Mathias , Schneck Jonathan P. , Webb Tonya J.
Published: April 2023

The source of GD3 impacts CD1d-mediated antigen presentation.(A) LCD1d cells were treated with GD3 from different sources for 4 hours, then washed extensively and cocultured with NKT cell hybridomas. IL-2 was measured, as an indication of NKT cell activation, by standard cytokine ELISA. (B) Pretreatment of a-GalCer loaded aAPC with GD3. a-GalCer loaded aAPC were incubated for 4hr with either medium, GD3, GD2, or ovarian cancer-associated ascites. The aAPC were washed extensively and then cocultured with a Va14+ NKT cell hybridoma, N38-3C3. NKT cell recognition of CD1d was assessed by measuring IL-2 production in the supernatants by ELISA.